menu

Quintiles Library

Show Filters
Article
These days, clinical trial sponsors are being asked to provide empirical evidence to many stakeholders with diverse needs and to do so efficiently. By taking a holistic view of post-approval evidence needs, it is possible to address many stakeholders' needs, thereby minimizing expense while increasing the likelihood of getting data that are fit for a variety of purposes.
Explore More
Article
When developing a new treatment for a rare disease, the first thing developers should do is build a patient registry for their target patient population. Rare disease patient registries are online platforms where patients and caregivers record information about their diagnosis, condition, and treatment experience. These platforms give developers a mechanism to gather...
Explore More
Article
Non-adherence is a shared issue, impacting all healthcare stakeholders. Patients will not gain the full benefit of their treatment, which may increase the need for medical intervention and even death. The healthcare system experiences inefficient use of resources and increased ong-term costs. The biopharma industry’s innovative products are not used effectively, leading...
Explore More
Fact Sheet
Implemented in July 2012, the new EU Pharmacovigilance regulations represent significant changes to human medicine regulation, shifting the focus of post-authorization safety from traditionally reactive risk management to the proactive analysis of product benefits as well as risks.
Read more
Press Release
RESEARCH TRIANGLE PARK, N.C. and MINNEAPOLIS – August 2, 2016 – Quintiles, the world’s largest provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners Inc., a leader in kidney care, today announced a global strategic alliance. The alliance combines DaVita’s world-class...
Read More
Infographic
Working together, Quintiles and DaVita can combine world-class renal clinical care expertise with industry-leading clinical research acumen to help you meet your timelines.
Read More
Fact Sheet
Selecting the right development partner is a balancing act. Do you want a local partner or one with access to extensive global resources? Broad or focused expertise? High touch or high tech? Low cost or high value? With the Quintiles Asia Pacific Emerging Biopharma Solution, you no longer have to compromise. Working on more than 60 studies for more than 45 Asia Pacific...
Read More
Article
Over the past 30 years, our greatest accomplishments in advancing understanding about the safety, effectiveness and value of healthcare interventions have been achieved through the availability and accessibility of health insurance claims for large populations and, more recently, access to pockets of electronic health records that can be linked to information on...
Explore More
Press Release
8.6% service revenue growth, 7.9% at constant currency, compared to the second quarter of 2015 $0.93 diluted adjusted EPS representing 19.2% growth compared to the second quarter of 2015, with $0.71 diluted GAAP EPS representing 6.0% growth $1.64 billion of net new business in the second quarter of 2016 up 24.4% compared to the second quarter of 2015,...
Read More
Article
Healthcare systems and a variety of stakeholders are demanding convincing value data to show improved outcomes before approving new drugs. Quintiles' experts share their insight into combining strategic thinking with the ability to capture and analyze complex clinical data to effectively demonstrate real-world outcomes.  Learn why a clear understanding of stakeholder...
Explore More
Fact Sheet
Achieve better patient outcomes with fit-for-purpose study design and execution to meet the needs of regulators, payers, providers and patients. Quintiles’ dedicated real-world evidence team combines integrated partner services and operational expertise with innovative technology to guide you through the unique challenges of real-world evidence studies. Click on the...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – July 13, 2016 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its second quarter 2016 financial results Wednesday, July 27, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT. The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at...
Read More
Presentation
Saumya Nayak, Manager, Patient and Site Services at Quintiles, shares insights into how China, the third largest pharmaceutical market, is following the US and Europe and shifting from product-centricity towards patient-centricity when conducting clinical trials. Topics discussed in this presentation are: Adopting a patient-centric clinical trial model The...
Explore More
Video
Dr. John Doyle & Jeanne Hecht discuss Evidence Optimization from DIA 2016. This presentation highlights innovative approaches to integrating evidence alongside scientific expertise, technology and global delivery.  
Video
Quintiles works with government officials, patient advocacy groups, physicians, and patents to accelerate knowledge sharing and decision making that benefits patients. From promoting proactive clinical trial legislation to promoting patient engagement, we engage many persons to improve the probability of success for sponsors and investigators.
Video
Jeanne Hecht discusses Transforming Patient Recruitment through Site & Patient Engagement at DIA 2016. Learn how we’re using innovative solutions and partnerships to transform the way patients impact study success.
Article
Patient registries have become a vital tool for clinical trials, giving researchers access to patient communities, advocates and real-world data to inform their protocols and improve their recruiting efforts. The impact of patient registries has been particularly beneficial for rare disease trials.
Explore More
White Paper
Imagine a world where predictive tools for development planning scour development programs and pharmaco-epidemiological real-world data to anticipate the response of patient populations. Where scenario analyses visualize strategic design trade-offs to optimize protocol design, and predictive assays select the right patients from integrated electronic health records across...
Explore More
White Paper
Quintiles’ HTA Watch is a web-based service offering instant access to a global repository of published HTA reports from nearly 100 agencies in 32 countries, providing regularly updated assessments to help inform life sciences and healthcare companies’ strategic decision-making*. In this edition of our HTA uncovered series, we will look specifically at the market access...
Explore More
Fact Sheet
While rare diseases individually affect very few patients, the collective impact is staggering. Globally, the list of rare diseases has grown to approximately 7,000, and 350 million people are living with a rare disease. These diseases are serious, often life-threatening, and approximately half of those affected are children. The lack of available treatments leave...
Read More